CPHI & PMEC Shenzhen 2026 runs from 16 to 18 September at the Shenzhen Convention & Exhibition Center, and the organizer expects visitors from 140 countries alongside more than 800 exhibitors. It is the South China edition of the CPHI portfolio, distinct from CPHI & PMEC China in Shanghai, and this year it leans hard on where the region has been investing: AI-enabled drug development, smart manufacturing, biologics and digital healthcare.
Shenzhen has become the focal point for China's pharmaceutical technology investment, and demand for access to the Greater Bay Area has grown with it. The organizer points to forecasts of a 41% compound annual growth rate for China's AI pharma market as the reason the technology zones have expanded.
Anne Schumacher, Group Director of Events & Business Development at Informa Markets, said the show "offers an unrivalled opportunity for international businesses to connect with the people, technologies and partnerships shaping the next generation of pharma".
More than 800 exhibitors are expected across pharmaceutical ingredients, biotech, AI technology and contract services, finished dosage, packaging and drug delivery, pharmaceutical machinery, laboratory equipment and clean technology.
A Hosted Buyer Programme connects qualified buyers and suppliers away from the stands, and the conference programme brings together academic and industry speakers on technological innovation, policy and market opportunities across South China.
Registration for a complimentary badge is open at reg.cphi-china.cn.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
| Headless Content Management with Blaze